Pacylex Pharmaceuticals CEO to Present on NMT Inhibitors as ADC Payloads at Summit
Pacylex Pharmaceuticals CEO to present on NMT inhibitors as ADC payloads at the 2nd Annual ADC Payload Summit in Boston. Learn about the potential breakthrough in cancer treatment with zelenirstat in Phase 1 trials.
This news highlights the potential breakthrough in cancer treatment using NMT inhibitors as ADC payloads, with zelenirstat showing promising results in Phase 1 trials. The presentation at the summit signifies a step forward in utilizing innovative therapies for hematologic and solid tumor cancers.
